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Background: In many cancer cells, L-type amino acid transporter 1 (LAT1) transports neutral amino acids
with bulky side chain, which activate mammalian target of rapamycin (mTOR) to cause cell proliferation.
An anti-diabetic drug, metformin, has been shown to activate AMP-activated protein kinase (AMPK),
which leads to inhibition of mTOR. LAT1 inhibition in combination with metformin could result in more
prominent suppression of mTOR activity.
Purpose: Anti-proliferative effect of a newly developed LAT1 speciﬁc inhibitor JPH203 in combination
with metformin is evaluated in 2 head and neck cancer cell lines, Ca9-22 and HEp-2 cells and in nude
mice inoculated with Ca9-22 cells.
Results and Discussion: By MTT assay, 0.5 mM metformin inhibited proliferation of Ca9-22 cells to
70% of control. In the presence of 100 mM JPH203, proliferation of Ca9-22 cells was inhibited to
60% of control. By combining these 2 drugs, proliferation of Ca9-22 was signiﬁcantly inhibited to
40% of control. However, this regimen was not very effective against HEp-2 cells. This combination
also suppressed in vivo growth of Ca9-22 cells in a xenotransplant model. A combination of anti-
LAT1 drug with metformin may be an effective anti-proliferative therapy for certain subsets of
cancers.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
L-type amino acid transporter 1 (LAT1) is a twelve-
transmembrane protein consisted of 512 amino acids (1). For
LAT1 to be expressed at the cell membrane and functional it has to
heterodimerize with another transmembrane protein 4F2hc via
disulﬁde bond. LAT1 belongs to system L, which transports largetyl-CoA carboxylase; AMPK,
; GAPDH, glyceraldehyde-3-
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d/4.0/).neutral amino acids (1,2). Its expression in a healthy individual is
either at the blood-organ barrier, i.e., brain, testis, and placenta, or
in rapidly proliferating cells such as bone marrow cells and cells in
embryonic tissues (1,3).
Notably, it is also expressed in various cancer cells, especially
highly malignant ones (4). This cancer cell speciﬁc expression
pattern can be used for diagnostic PET scan, where probes are
substrates for LAT1 (5e8). LAT1 expression becomes higher as
cancers become more malignant (9) and its expression levels have
been shown to negatively correlate with length of survival in
several cancers (10,11). Highly malignant cancers in general grow
rapidly requiring energy (glucose) and biomolecular synthesis
(amino acids and sugars for protein and nucleic acids) (12). One of
the important signals leading to protein synthesis comes from
activation of mammalian target of rapamycin (mTOR) pathway
(12e14). Some amino acids (especially leucine) stimulate mTOR
independent of growth factor signals (14). Between 2 differentnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Table 1
Primer pairs and probes used for Taqman PCR.
Transporters Primers and probes
LAT1 forward GGAAGGGTGATGTGTCCAATCT
reverse TTCAAGTAATTCCATCCTCCATAGG
probe FAM-CCCAACTTCTCATTTGAAGGCACCAAACT-TAMRA
LAT2 forward AAATCTGGAGGTGACTACTCCTATGTC
reverse GTAGATCACCAGCACAGCAATCC
probe FAM-TCTTCGGAGGACTGGCTGGGTTCC-TAMRA
LAT3 forward CCCCAACTCAGGGCACTGT
reverse GTAGCGTGGTCTGATGGATTTG
probe FAM-CTCGGAGATGCCAGGGACGGG-TAMRA
LAT4 forward GCCCCTGGGTATCGTCATG
reverse CGTACGCAATCAGCAAGCA
probe FAM-CAGCGCCTGCTTCGCGGTTT-TAMRA
4F2hc forward TGGCTCCAAGGAAGATTTTGAC
reverse GTTGGGAGTAAGGTCCAGAATGAC
probe R6G-TGCAATCGGCTAAAAAAAAGAGCATCCG-BHQ2
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mTORC2, amino acids are shown to stimulate mTORC1 pathway
(14). Because leucine is transported by system L and many cancer
cells express LAT1 among system L transporters, LAT1 can be
regarded as an upstream regulator of mTORC1 in such cancer cells
and LAT1 inhibition has been reported to be a promising cancer
therapy (15,16). Pan LAT inhibitor BCH is used in these studies (17).
However, its lower potency and non-selectiveness prevents BCH
itself from becoming a therapeutic drug. Recently, a more potent
LAT1 speciﬁc inhibitor, JPH203, is shown to inhibit cancer cell
growth in vitro in a human colon cancer cell line and in vivo in a
xenotransplant model (18).
Independent of amino acid pathway, mTOR is also regulated by
energy status of the cell (19). In energy depleted cells, AMP con-
centration increases while ATP concentration decreases. High
concentrations of intracellular AMP activate AMP-activated protein
kinase (AMPK), which leads to inhibition of mTOR activity (20). In a
similar fashion as in energy depleted cells, an anti-diabetic drug
metformin activates AMPK (19). Interestingly, there are several
reports on anti-tumor effect of metformin (21,22) and an epide-
miological study in type 2 diabetes patients shows that patients
treated with metformin are less likely to develop cancer compared
to patients without metformin (23).
Thus, addition of metformin to JPH203 would suppress mTOR
pathway more strongly than either drug alone and this could lead
to more effective inhibition on cancer cell proliferation.
2. Materials and methods
2.1. Reagents
An LAT1-speciﬁc inhibitor, JPH203 ((S)-2-amino-3-(4-((5-
amino-2- phenylbenzo [d] oxazol-7-yl) methoxy)-3,5-dichlor-
ophenyl) propanoic acid), was provided by J-Pharma Co., Ltd.
(Yokohama, Japan) (18). Metformin (1, 1-Dimethylbiguanide, Hy-
drochloride) was purchased from Merck KGaA (Darmstadt, Ger-
many). All the other reagents were purchased from Sigma unless
otherwise indicated.
2.2. Cell culture
Two human head and neck squamous cell cancer lines, Ca9-22
and HEp-2, were used. Ca9-22 cells were purchased from Japa-
nese Collection of Research Bioresources (Osaka, Japan). HEp-2 cells
were obtained from American Type Culture Collection (ATCC,
Manassas, VA, USA). These cell lines were cultured in Eagle's Min-
imum essential medium (MEM) with 10% fetal bovine serum (Life
Technologies, Carlsbad, CA, USA), 100 units/mL penicillin, and
100 mg/mL streptomycin in a humidiﬁed incubator with 5% CO2 at
37 C.
2.3. [14C]L-leucine uptake assay
Cells were seeded on 24-well plates two days before experi-
ment. After the cells were washed three times with standard up-
take solution (125 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM
MgSO4, 25mMHEPES,1.2mMKH2PO4 and 5.6mMglucose, pH 7.4),
they were pre-incubated with JPH203 and/or metformin for 10 min
at 37 C. For Naþ free condition, 125 mM choline chloride was used
instead of 125 mM NaCl. Cells were incubated with 20 mM leucine
including 1 mM [14C]L-leucine for 2 min. After washing three times
with ice-cold uptake solution, the cells were solubilized with 0.1 N
NaOH, added OptiPhase Supermix (PerkinElmer, Waltham, MA,
USA) and the radioactivity was measured by a liquid scintillation
counter.2.4. Measurement of protein concentration
Protein concentration was measured using Bio-Rad Protein
Assay Dye Reagent (Bio-Rad Laboratories, Hercules, CA) with
bovine serum albumin as a standard.
2.5. Quantitative reverse transcription polymerase chain reaction
(qRT-PCR)
Total cellular RNA was isolated and puriﬁed from cells using
Isogen (Nippon Gene, Tokyo, Japan) according to the manufac-
turer's instruction. RNA samples were treated with RNase-free
DNase RQ1 (Promega Corporation, Madison, WI, USA) and puri-
ﬁed by suspending into phenol/chloroform/isoamyl alcohol
(25:24:1) solution. The ﬁrst-strand complementary DNA (cDNA)
was synthesized using MuLV Reverse Transcriptase (Life Technol-
ogies, Carlsbad, CA, USA) with oligo dT primer. Real-time PCR for
LAT1, LAT2, LAT3, LAT4 and 4F2hc was conducted with 7300 Real-
Time PCR system (Life Technologies, Carlsbad, CA, USA) Designed
primers and TaqMan probes were shown in Table 1. GAPDH was
quantiﬁed with TaqMan GAPDH control Reagents (Human) (Life
Technologies, Carlsbad, CA, USA). All samples were analyzed in
triplicates.
2.6. Immunocytochemistry
Cells werewashedwith PBS containing 1mMMgCl2 and 0.1mM
CaCl2 (PBSþþ), ﬁxed in cold methanol for 7 min and washed 3 times
with PBSþþ. Fixed cells were incubated with permeabilization
buffer (0.1% BSA, 1% Triton X-100 in PBSþþ) for 15 min and blocked
in goat serum dilution buffer (GSDB), (10% goat serum, 1% Triton X-
100, 10 mM glycine in PBSþþ) for 60 min. Cells were incubated with
primary antibodies diluted in GSDB buffer overnight at 4 C and
washed 3 times with permeabilization buffer, then incubated with
anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 568 con-
jugated IgG (Life Technologies, Carlsbad, CA, USA) diluted in GSDB
buffer for 1 h, after which they were washed 3 times in PBSþþ and
once in water. Cells were mounted in ﬂuorescence mounting me-
dium (DAKO JAPAN, Tokyo, Japan) and was visualized with an
Olympus Fluoview FV500 laser confocal microscope (Olympus,
Tokyo, Japan).
2.7. Cell viability assay
Ca9-22 and HEp-2 cells were seeded in 24-well plate in normal
growth medium. After 2 days of incubation, cells were treated with
JPH203 and/or metformin, followed by incubation for 7 days. Cell
S. Ueno et al. / Journal of Pharmacological Sciences 131 (2016) 110e117112viability was measured by MTT assay. 0.45 mg/mL MTT (3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide; Life Tech-
nologies, Carlsbad, CA, USA) was added to the cells. The cells were
incubated for 4 h. After aspiration of medium containing MTT,
isopropanol with 0.04 N HCl was added and absorbance was
measured at 570 nm using SH-9000Lab (CORONA ELECTRIC, Ibar-
aki, Japan).
2.8. Western blot analysis
Ca9-22 and HEp-2 cells were seeded in 6-well plates in the
normal growth medium and allowed 2 days for growth. In the
case of phospho-p70S6 kinase (p70S6K) detection, serum was
depleted overnight. Then Amino acids were depleted 2 h by
incubating the cells in Hank's Balanced Salt Solution (Life Tech-
nologies, Carlsbad, CA, USA). Medium were then changed to
either, growth medium without serum but with amino acids
(positive control; S6K should be phosphorylated), the same
amino acid replete medium containing 0.5 mM metformin and/or
100 mM JPH203 and the cells were incubated another 30 min. In
the case of phospho-acetyl-CoA carboxylase (pACC) detection, the
cells were incubated overnight in serum free medium in the
absence (control) or presence of 0.5 mM metformin. After
washing with ice-cold PBS, the cells were harvested by scraping
in lysis buffer (150 mM NaCl, 0.5 mM EDTA, 1% Triton X-100 and
50 mM TriseHCl, pH 7.4) with cOmplete, Mini, EDTA-free
protease inhibitor cocktail (Roche Applied Science, Mannheim,
Germany). After incubation at 4 C for 1 h, cell lysates were
centrifuged for 30 min at 14,000 rpm. The supernatants (30 mg of
protein) were subjected to SDSePAGE, followed by transferring
to Immobilon-P PVDF membrane (Merck KGaA, Darmstadt,
Germany). The membrane was incubated with either primary
antibodies: phosphor ACC, phosphor S6K from Cell Signaling
Technology (Danvers, MA, USA), b-actin (Clone AC-15), LAT1
(TRANS GENIC, Kumamoto, Japan) and 4F2hc (Santa Cruz
Biotechnology, Dallas, Texas, USA) antibody. After washing three
times with Tris buffered saline with Tween 20 (TBS-T) (137 mM
sodium chloride, 20 mM Tris, 0.1% Tween-20), these membranes
were incubated with goat anti-mouse or anti-rabbit IgG (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA). The mem-
brane was washed three times with TBS-T. Chemiluminescence
detection images and densitometry were obtained with Image-
Quant LAS-4000 (Fujiﬁlm, Tokyo, Japan).
2.9. Apoptosis assay
Ca9-22 and HEp-2 cells were seeded in 96-well plates in the
normal growth medium and allowed 2 days for growth. Cells were
treated with JPH203 and/or metformin, followed by incubation for
2 days. Apoptosis was measured by the Caspase-Glo® 3/7 Assay kit
from Promega Corporation (Madison, WI, USA) according to its
protocol.
2.10. Xenograft model anti-tumor assay
Nude mice, BALB/cSlc-nu/nu (Japan SLC, Inc, Hamamatsu,
Japan), was used for xenotransplantation. Cyclophosphamide was
administrated by intraperitoneal injection at 100 mg/kg one day
before transplantation of Ca9-22 cells. Mixture of 0.5 107 Ca9-22
cells and Matrigel™ basement membrane matrix (BD Biosciences,
Bedford, MA, USA) was injected into nude mice subcutaneously.
Eight mice were prepared for each condition. After 4 weeks,
intravenous administration of JPH203 (6 mg/kg) and/or oral
administration of metformin (300 mg/kg) was started. These
drugs were administered once a day and continued for 14 days.Tumor volume (volume ¼ (width)2  length/2) was measured
with micrometer calipers and observed over the treatment time.
Toxic effect was evaluated by necropsy after administration of
drugs.
2.11. Animal ethics statements
This study was carried out in strict accordance with the rec-
ommendations in the Guide for the Care and Use of Laboratory
Animals of Ministry of Education, Culture, Sports, Science and
Technology-JAPAN. The protocol was approved by Institute of
Laboratory Animals, Graduate School of Medicine, Kyorin Univer-
sity (The Experimental Animal Ethics Committee in Kyorin Uni-
versity, permit number 92).
2.12. Statistical analysis
Welch's t-test was used to compare all experimental results. A P-
value less than 0.05 was considered signiﬁcant.
3. Results
3.1. LAT1 was mainly responsible for leucine uptake in head and
neck cancer cell lines, Ca9-22 and HEp-2
Because leucine is a neutral amino acid with bulky side chain
and known to stimulate mTOR most effectively (24), leucine was
used as a prototypical substrate. It has been shown that leucine is
transported by Naþ-dependent or Naþ-independent systems (25).
As shown in the Fig. 1A, presence of Naþ did not change leucine
uptake to a major degree in both cells; Naþ-independent leucine
uptake was 90% of total uptake in Ca9-22 cells and 81% in HEp-2
cells, indicating that Naþ-independent system L is mainly
responsible for leucine uptake in these cells. Among 4 members of
system L transporters, only LAT1 was expressed in a signiﬁcant
amount in both Ca9-22 and HEp-2 cells by qRT-PCR (Fig. 1B). LAT1
and co-expressing molecule 4F2hc proteins were detected in
these cells by western blotting (Fig. 1C). It should be noted that
both mRNA and protein level expression of LAT1 was much higher
in Ca9-22 cells than HEp-2 cells; at mRNA level, LAT1 expression
of Ca9-22 cells was 6-fold higher than that of HEp-2 cells (Fig. 1B),
and densitometry of LAT1 signals in a western blot showed that
LAT1 protein in Ca9-22 cells were 12-fold higher than that in HEp-
2 cells (Fig. 1C). Immunocytochemical analysis conﬁrmed that cell
surface expression of these proteins in Ca9-22 and HEp-2 cells
(Fig. 1D).
3.2. LAT1 inhibition led to suppression of both leucine uptake and
proliferation
Consistent with the aforementioned result that LAT1 was the
major Naþ-independent system L transporter expressed in these
cell lines, JPH203, a speciﬁc inhibitor for LAT1, blocked up to 78%
(10 mM) or 85% (100 mM) of leucine uptake into Ca9-22, 62% (10 mM)
or 71% (100 mM) of leucine uptake into HEp-2 cells, respectively
(Fig. 2A).
As shown in Fig. 2B, addition of JPH203 to the culture sup-
pressed proliferation of Ca9-22 or HEp-2 cells with similar potency
in a dose-dependent fashion with IC50 (half maximal inhibitory
concentration) of low 100 mM range.
Expression of LAT1 and 4F2hc after treatment with JPH203 for
30 min and 7 days was examined (Fig. 2C). LAT1 or 4F2hc expres-
sion in Ca9-22 and HEp-2 cells was not changed at 30 min and
slightly upregulated at 7 day.
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Fig. 1. Expression and function of L type amino acid transporter in head and neck cancer cells. (A) Effect of sodium on [14C]L-leucine uptake in Ca9-22 and HEp-2 cell lines.
Radioisotope-labeled leucine uptake was measured for 2 min in the presence or absence of 125 mM NaCl. Leucine uptake was calculated by the amount of incorporated leucine per
1 mg protein during 2 min of incubation. Each data point represents mean ± SEM (n ¼ 4). (B) Levels of mRNA expression of LATs and 4F2hc normalized to those of GAPDH (¼100) in
Ca9-22 and HEp-2 cells. (C) Western blot analysis of LAT1 and 4F2hc in HEp-2, Ca9-22 detected with anti-LAT1, anti-4F2hc and b-actin. (D) Immunocytochemistry of LAT1/4F2hc in
HEp-2 and Ca9-22 cells. From left to right columns: DAPI (diamidino-2-phenylindole is a blue ﬂuorescent stain speciﬁc for DNA) nuclear staining (blue), LAT1 immunostaining (red),
4F2hc immunostaining (green), and merged pictures. Scale bars ¼ 40 mm.
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Metformin is an anti-diabetic drug and activates AMPK by
increasing cytosolic AMP concentrations (26). Activation of AMPK
could suppress cell proliferation through inhibition of mTOR.
Decreased viabilities of Ca9-22 or HEp-2 cells were observed in the
presence of metformin (Fig. 3A). When Ca9-22 or HEp-2 cells were
cultured in the presence of various concentrations of metformin,
their growth measured by MTT assay was suppressed to the similar
extent, IC50 being around 1 mM.
Western blot was performed to conﬁrm AMPK activation by
metformin. Acetyl-CoA carboxylase (ACC) is one of the well docu-
mented substrates of AMPK. As shown in Fig. 3B, metformin
increased phosphorylation of ACC in both Ca9-22 and HEp-2 cells.
3.4. Effect of metformin-JPH203 combination on cell proliferation
was cell-type dependent
In order to elucidate the synergism between metformin and
JPH203, the lowest concentration of each drug that consistently
suppressed growth of both Ca9-22 and HEp-2 cells was chosen. In
Ca9-22 cells, 0.5mMofmetformin suppressed their growth to ~70%
of control and 10 mM of JPH203 suppressed their growth to ~60% of
control (Fig. 4A). When the cells were cultured in the presence of
both metformin and JPH203, their growth was suppressed to ~40%
of control (Fig. 4A), which was expected if these 2 drugs actindependently (this concentration of metformin suppressed pro-
liferation to ~70% of control and this concentration of JPH203 to
~60% of control, thus 60  70 ¼ ~40% of control would be expected
if these 2 drugs act independently). In HEp-2 cells, the same con-
centration of metformin and JPH203 suppressed their growth to
~80% and ~75% of control, respectively (Fig. 4B). Co-administration
of metformin and JPH203 suppressed their growth to ~70% of
control, which was statistically signiﬁcant compared to the growth
observed in the presence of JPH203 alone (Fig. 4B). However, unlike
Ca9-22 cells, the degree of growth suppression by combining 2
drugs was less than expected (~60% of control was expected if these
2 drugs act independently).
Since intracellular depletion of leucinewas expected to suppress
mTOR signaling via mTORC1, phosphorylation status of mTOR
itself and its downstream effecter p70S6K were examined in the
absence/presence of JPH203 in Ca9-22 and HEp-2 cells (Fig. 5).
Removal of amino acids from culture medium led to de-
phosphorylation of mTOR and p70S6K. When amino acids were
added back to themedium,mTOR and p70S6Kwas phosphorylated.
Phospho-p70S6K level was greatly decreased in the presence of
JPH203 in Ca9-22 cells, while such suppression was not detectable
in HEp-2 cells.
It has been reported that inhibition of LAT1 by BCH and JPH203
leads apoptosis on cancer cell lines (17,27). We tested the effect of
metformin and JPH203 on caspase activity to check whether
apoptosis is induced after drug treatment (Table 2). Metformin
AB
0
0.5
1
1.5
2
2.5
3
3.5
4
control 1 μM JPH 10 μM JPH control 1 μM JPH 10 μM JPH
Ca9-22 HEp-2
Le
u 
up
 ta
ke
 ( 
μm
ol
/ m
g 
pr
ot
ei
n 
/ m
in
 )
0.0
20.0
40.0
60.0
80.0
100.0
120.0
0.1 1 10 100 1000
Ca9-22
HEp-2
C
el
l v
ia
bi
lit
y 
 ( 
%
 o
fc
on
tro
l )
concentration of JPH 203 (μM)
4F2hc
LAT1
β-actin
Ca9-22 HEp-2
co
ntr
ol
30
mi
n
7 d
ays
co
ntr
ol
30
mi
n
7 d
ays
C
Fig. 2. Effect of JPH203 on leucine uptake and proliferation. (A) Inhibition of [14C]L-leucine uptake by JPH203. [14C]L-leucine uptake was measured at 2 min in the absence
(control) or presence of indicated concentrations of JPH203 in Ca9-22 and HEp-2 cells. Leucine uptake was calculated by the amount of incorporated leucine per 1 mg protein during
2 min of incubation in standard uptake solution. Each bar represents mean ± SEM (n ¼ 4). (B) Effect of JPH203 on cancer cell viability. After treatment with various concentrations
(0.1, 1.0, 10, 100, 1000, 5000 mM) of JPH203 for 7 days, Ca9-22 or HEp-2 cell viability was measured byMTT assay. Y axis: relative cell viability represents as % control (non-treated cell
viability ¼ 100%). X axis: JPH203 concentration (mM) in a log scale. Each data point represents mean ± SEM (n ¼ 4). (C) Western blot analysis of LAT1 and 4F2hc in HEp-2, Ca9-22
after treatment with JPH203 for 30 min or 7 days detected with anti-LAT1, anti-4F2hc and b-actin.
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22 cells. JPH203 treatment led to activation of caspase. Combina-
tion of JPH203 and metformin decreased the level of caspase acti-
vation compared to JPH203 alone.
3.5. Metformin-JPH203 combination suppressed Ca9-22 cell growth
in vivo in a xenotransplant model
Combination effect of metformin and JPH203 was investigated
in vivo using Ca9-22 cells transplanted into nude mice (Fig. 6). At
the end of 14-days treatment 6 mg/kg JPH203 had minimal, if any,
effect on tumor growth and 300mg/kgmetformin tended to inhibit
tumor growth, although this suppression did not reach statistical
signiﬁcance compared with control treatment. Combination of
metformin and JPH203 inhibited tumor growth more than each
drug alone and to a degree statistically signiﬁcant compared with
control treatment. Necropsy of these animals did not reveal any
toxic effects.
4. Discussion
Head and neck cancer occurs mainly in elderly people. In such
patients, a strong cytotoxic chemotherapy or radical surgerydecreases quality of life and it is often impossible to take these
therapies even when they are deemed to be curative. Less toxic
anti-cancer treatment regimens would be more desirable. This
study demonstrated that the main route of leucine uptake in 2 head
and neck cancer cell lines (Ca9-22 and HEp-2 cells) was via system L
and LAT1 was the only system L transporter expressed in a signif-
icant quantity in these cells. A newly developed LAT1 speciﬁc in-
hibitor JPH203 not only inhibited leucine uptake and proliferation
of these cells, but also induced apoptosis. But it is not as potent as
classic cytotoxic chemotherapy drugs. Metformin activated AMPK
and exhibited growth inhibitory effect of Ca9-22 and HEp-2 cells
with similar potency although a much higher concentration was
required than diabetes treatment. If metformin and JPH203 would
work synergistically, it might be possible to enhance potency of
JPH203 and avoid toxicity of metformin. When JPH203 and met-
formin were combined, growth suppression was enhanced in both
cells but the degree of inhibitionwas higher in Ca9-22 cells. In Ca9-
22 cell xenotransplantmodels, similar results were obtained and no
toxicity was observed after administration of two drugs.
It is promising that the combination of sub IC50 concentrations
of metformin and JPH203 led tomore than 50% growth suppression
in Ca9-22 cells (Fig. 4). The fact that metformin and JPH203 acted in
an additive fashion rather than synergistic in Ca9-22 cells (Fig. 4A)
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protein) were subjected to SDS-PAGE and western blot analysis.
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Fig. 5. Effect of JPH203 and metformin on activity of mTOR and p70S6K. Western
blot analysis of mTOR and p70S6K in metformin and/or JPH203 treated cells. After
HEp-2/Ca9-22 cells were incubated in the serum free growth medium overnight, then
amino acids were removed for two hours. Medium were changed to either, growth
medium without serum but with amino acids, the same amino acid replete medium
containing 0.5 mM metformin and/or 100 mM JPH203 and cells were incubated
another 30 min. Whole cell lysates (30 mg of protein) were subjected to SDS-PAGE and
western blot analysis.
S. Ueno et al. / Journal of Pharmacological Sciences 131 (2016) 110e117 115suggests that metformin and JPH203 inhibited growth via inde-
pendent mechanism. Metformin was shown to activate AMPK
(Fig. 3B) and AMPK is known to suppress mTORC1 activity via
activation of TSC2 (28). JPH203 inhibited leucine uptake (Fig. 2A),
cell proliferation (Fig. 2B), and mTOR activity (mTORC1 activity)
(Fig. 5) in Ca9-22 cells. A recent study revealed that amino acids are
sensed by Rag GTPases at the lysosomal membrane and mTORC1 is
recruited to the surface of the lysosome (29). Thus, it is likely that
input from Rag and TSC2 is processed independently in mTORC1.
Why was the combination of JPH203 and metformin in HEp-2
cells not as effective (Fig. 4) despite the similar potency of these
drugs as in Ca9-22 cells (Figs. 2B and 3A)? Effect of metformin is
similar in HEp-2 and Ca9-22 cells (Fig. 3B). In contrast, regulation
of LAT1-amino acid-mTORC1-p70S6K pathway appears different
between these cells; suppression of p70S6K phosphorylation by
JPH203 was less in HEp-2 cells than in Ca9-22 cells (Fig. 5). This
Table 2
Effect of JPH203 and metformin on caspase 3/7 activity.
HEp-2 (%) Ca9-22 (%)
Captisol 100 100
Metformin 106.5 ± 2.7 84.4 ± 3.2
JPH203 204.9 ± 3.3 190.5 ± 12.1
Metformin þ JPH203 179.4 ± 5.2 155.1 ± 8.8
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Fig. 6. Effect of JPH203 and metformin on xenograft tumor progression. Ca9-22
cells were injected into nude mice subcutaneously and JPH203 and metformin was
given by intravenous injection and oral administration, respectively, once a day and
continued for 14 days. The drug treatment was started after 4 weeks of tumor inoc-
ulation. Tumor volume was calculated as volume ¼ (width)2  length/2 and the data
were shown in ratio compared to the volume just before the drug administration,
which was designated as 100%. *P < 0.05.
S. Ueno et al. / Journal of Pharmacological Sciences 131 (2016) 110e117116observation led us to speculate that relative contribution of
mTORC1 pathway in proliferation may be less in HEp-2 cells than
Ca9-22 cells. However, JPH203 was as effective in HEp-2 cells as
in Ca9-22 cells (Fig. 2B), suggesting that mechanisms other than
inhibition of mTORC1-p70S6K might be acting for JPH203 in
HEp-2 cells. Such mechanism requires further investigation.
Regardless of the mechanisms, it should be emphasized that not
all cancers are likely to respond to this combination therapy.
Thus, it is very important to ﬁnd biomarkers predicting respon-
siveness to the combination therapy and we are in the process of
investigation.
As shown in Table 2, metformin by itself had no effect on
apoptosis in HEp-2 cells while it had slight suppressive effect on
that in Ca9-22 cells. JPH203 induced apoptosis and combination
treatment decreased caspase activation compared with that in
JPH203 treatment in both of these cells, suggesting that metformin
has anti-apoptotic effect in this context. These results are not
consistent with other literature that show pro-apoptotic effect of
metformin (30e32). However, metformin was also reported to
show anti-apoptotic effect (33) in certain context. This may be one
of the reasons that metformin and JPH203 did not act synergisti-
cally in these cells.
It is encouraging that the combination of JPH203 andmetformin
inhibited in vivo cancer cell growth in a xenotransplant model(Fig. 6). The absolute degree of growth suppression (~80% of con-
trol) might not be as dramatic as classic cytotoxic anti-cancer drugs.
However, the treatment appeared free from toxic side effects. Mild
tumor growth suppression plus no signiﬁcant toxic side effects
might translate into superior quality of life in cancer patients.5. Conclusions
Metformin additively enhanced anti-proliferative effect of an
LAT1 speciﬁc inhibitor, JPH203, in Ca9-22 head and neck cancer cell
line both in vitro and in vivo. In this cell line, AMPK activation by
metformin and amino acid depletion by JPH203 may indepen-
dently act on mTORC1 and suppress its activity.Conﬂict of interest statement
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